Drug intelligence / Profile preview

VLA1554

Development stage: Preclinical
Lead developer: Valneva
Modality: Vaccines & Immunotherapeutics

Overview

VLA1554 is a vaccine candidate developed by Valneva targeting human metapneumovirus (hMPV), a major respiratory pathogen responsible for acute upper and lower respiratory tract infections, particularly in children, immunocompromised patients, and older adults. hMPV is associated with significant morbidity and mortality worldwide. The mechanism of action for VLA1554 is immunostimulation via vaccination against hMPV. As of the latest available information, VLA1554 remains in preclinical development[2][3].

Targets

HMPV F (Human metapneumovirus fusion protein)

Beyond the preview

Go deeper on VLA1554.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLA1554.

Explore the full profile